Long-Term Cognitive Safety of Achieving Very Low LDL Cholesterol with Evolocumab
Exposure to very low levels of LDL cholesterol, achieved via PCSK9 inhibition and statin therapy, was not associated with cognitive impairment through long-term follow-up. Further studies are needed to assess the generalizability to adults at higher risk of dementia.
Authors
- Xinhui Ran
- ANTHONY C. KEECH (ORCID: https://orcid.org/0000-0002-9426-9136)
- Kenton H. Zavitz
- Marc S. Sabatine (ORCID: https://orcid.org/0000-0002-0691-3359)
- Robert P. Giugliano (ORCID: https://orcid.org/0000-0003-4110-7675)
- Maria Laura Monsalvo (ORCID: https://orcid.org/0000-0002-4113-9418)
- Brian R. Ott (ORCID: https://orcid.org/0000-0002-4899-7116)
- Dan Atar (ORCID: https://orcid.org/0000-0003-1513-8793)
- Michelle L. O’Donoghue (ORCID: https://orcid.org/0000-0002-8663-0067)
- André Zimerman (ORCID: https://orcid.org/0000-0001-8977-6929)
- François Mach (ORCID: https://orcid.org/0000-0003-3178-9131)
- Bei Wang (ORCID: https://orcid.org/0000-0001-9336-4505)
- Christopher E. Kurtz
- KyungAh Im
Institutions
- Oslo University Hospital (NO)
- Brigham and Women's Hospital (US)
- Amgen (United States) (US)
- Harvard University (US)
- University of Oslo (NO)
- Brown University (US)
- Hospital Moinhos de Vento (BR)
- Cambridge Cognition (United Kingdom) (GB)
- Thrombolysis in Myocardial Infarction Study Group (US)
- National Health and Medical Research Council (AU)
- Geneva College (US)
Publication Details
- Journal
- NEJM Evidence
- Published
- 2024-12-24
- DOI
- https://doi.org/10.1056/evidoa2400112
- Citations
- 15
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.59